Abstract

Checkpoint kinase 1 (CHK1) is critical for S-phase fidelity and preventing premature mitotic entry in the presence of DNA damage. Tumor cells have developed a strong dependence on CHK1 for survival, and hence, this kinase has developed into a promising drug target. CHK1 deficiency in mice results in blastocyst death due to G2/M checkpoint failure showing that it is an essential gene and may be difficult to target therapeutically. Here, we show that chemical inhibition of CHK1 kills murine and human hematopoietic stem and progenitor cells (HSPCs) by the induction of BCL2-regulated apoptosis. Cell death in HSPCs is independent of p53 but requires the BH3-only proteins BIM, PUMA, and NOXA. Moreover, CHK1 is essential for definitive hematopoiesis in the embryo. Noteworthy, cell death inhibition in HSPCs cannot restore blood cell formation as HSPCs lacking CHK1 accumulate DNA damage and stop dividing. Moreover, conditional deletion ofCHK1 in hematopoietic cells of adult mice selects for blood cells retaining CHK1, suggesting an essential role in maintaining functional hematopoiesis. Our findings establish a previously unrecognized role for CHK1 in establishing and maintaining hematopoiesis.

Keywords  apoptosis; BCL2; CHK1; DNA damage; hematopoietic stem cells

Subject Categories  Autophagy & Cell Death; Cell Cycle; Stem Cells

DOI 10.15252/embr.201847026 | Received 7 September 2018 | Revised 22 May 2019 | Accepted 24 May 2019 | Published online 17 June 2019

EMBO Reports (2019) 20: e47026

Introduction

Long-term HSCs (LT-HSCs) in the adult have self-renewal capacity but reside in a quiescent state for most of their lifetime [1]. LT-HSCs divide asymmetrically into one daughter with short-term (ST) reconstitution potential, differentiating into a multi-potent progenitor (MPP) cell and the other daughter remaining a bona fide stem cell [2,3]. MPPs then commit to the myeloid, lymphoid, or erythroid/megakaryocyte lineage. These transient amplifying cells with limited lineage potential provide the organism with all blood cells needed. To fulfill this task over a lifetime, cell cycle entry and quiescence of LT-HSCs and their immediate progeny are tightly regulated, e.g., intrinsically by the polycomb-protein BMI1 and the p53 tumor suppressor [1,4] but they also respond to trophic signals from the bone marrow micro-environment in the stem cell niche [5–7], as well as to systemic cues, elicited in response to viral or microbial infections, most notably interferons [8,9].

The serine/threonine kinase checkpoint kinase 1 (CHK1) is a critical cell cycle regulator that controls normal proliferation and is activated in response to DNA damage, thereby also controlling p53 function [10,11]. Especially upon single-stranded DNA breaks, ataxia-telangiectasia and Rad3-related protein (ATR) phosphorylates CHK1, leading to its activation and stabilization [12]. On the one hand, active CHK1 arrests the cell cycle via inhibition of CDC25 phosphatases that are essential for the activity of Cyclin/CDK complexes. CHK1-phosphorylated CDC25A is marked for ubiquitination and therefore proteasomal degradation leading to a drop in CDK2 activity and subsequent G1/S arrest [13,14]. On the other hand, CDC25C is retained in the cytoplasm by 14-3-3 proteins when phosphorylated by CHK1 upon DNA damage, restraining CDK1 activity leading to a G2/M arrest [15]. Moreover, CHK1 promotes the activity of MYT1 and WEE1 kinases that both inhibit CDK1 by phosphorylation, blocking transition from G2 to M-phase [16,17]. Under these conditions, CHK1 can stabilize p53 by direct phosphorylation to tighten cell cycle arrest [18,19]. In the absence of p53, however, cells become highly dependent on CHK1 for cell cycle control, arrest, and repair of DNA damage [12,14], generating a vulnerability that is currently explored as a means to treat cancers with CHK1 inhibitors [11,20].

CHK1 deletion in mice was shown to be embryonic lethal around E5.5 due to G2/M checkpoint failure. Blastocysts lacking CHK1...
exhibit massive DNA damage and cell death that could not be overcome by co-deletion of p53 [21,22]. All of this supports the essential function of Chk1 in cell cycle regulation and the DNA damage response to avoid mutational spread and genomic instability. Of note, a certain percentage of Chk1−/− mice was reported to develop anemia with age, suggesting critical dose-dependent roles in erythropoiesis [23] while conditional deletion of Chk1 in B and T cells was shown to arrest their development at early proliferative stages due to accumulation of DNA damage and increased cell death [24,25]. This suggests that blood cancer treatment with chemical inhibitors targeting CHK1 may cause collateral damage within the healthy hematopoietic system, at least in cycling lymphoid or erythroid progenitors, yet the role of Chk1 in early hematopoiesis and stem cell dynamics as well as for adult blood cell homeostasis remains unexplored.

It was reported that Chk1 mRNA is expressed at significant levels in HSC [23] despite the fact that HSC remain quiescent for the majority of their lifetime. Given the fact that HSC accumulate DNA damage when exiting dormancy [26,27], e.g., under pathological conditions such as substantial blood loss or in response to infection [8,9,28], as well as during natural aging [29,30], it appears appropriate that HSCs arm themselves with CHK1 to immediately deal with the dangers of a sudden proliferative challenge to avoid mutational spread. Yet, another study found that Chk1 mRNA levels are low in HSC but increase during proliferation-coupled self-renewal or differentiation, along with other DNA damage response and repair genes [29]. Consistent with a direct link to proliferation, Chk1 mRNA was also found to be higher in fetal liver vs. bone marrow-derived HSC from young or aged mice [29]. Notably here, HSC from old mice suffer from enhanced replication stress upon mobilization that triggers substantial CHK1 activation [30]. Together, this suggests critical roles for CHK1 in stem cell dynamics and prompted us to elucidate its role in the development and survival of hematopoietic stem and progenitor cells. Using a conditional allele for Chk1 in combination with a CRE-deleter strain allowing recombination of this allele within the hematopoietic system, we were able to highlight the importance of Chk1 for the establishment of hematopoiesis in the embryo and the survival of HSCs from mice and men.

Results

CHK1 inhibition limits the survival of hematopoietic progenitors by inducing mitochondrial apoptosis

To explore the consequences of CHK1 inhibition on cycling multipotent hematopoietic precursors, we first assessed the response of Hoxb8-immortalized FLT3-dependent progenitor cells (Hoxb8-FL cells). These cells can be generated from murine bone marrow and are multi-potent progenitor (MPP)-like cells that can be differentiated in vitro into myeloid and lymphoid lineages [31]. Treatment of Hoxb8-FL cells with two specific CHK1 inhibitors (CHK1i), PF-477736 (PF) or CHIR-124 (CHIR), resulted in time- and dose-dependent cell death, as assessed by propidium iodide (PI) staining of DNA content by flow cytometric analysis (Figs 1A and EV1A, left panel). Hoxb8-FL cells generated from Vav-BCL2-transgenic mice or mice lacking the key-apoptotic effectors Bax and Bak were protected from cell death, indicating initiation of caspase-dependent mitochondrial apoptosis after CHK1i treatment (Figs 1A and EV1A). Consistently, addition of the pan-caspase inhibitor QVD prevented CHK1i-induced cell death (Fig 1B). The rapid cell death seen in wild-type cells was accompanied by γH2AX accumulation, p53-stabilization, and PARP1 cleavage, as detected in western analyses (Fig 1C). As γH2AX phosphorylation is also induced during apoptosis due to CAD-mediated cleavage of DNA between nucleosomes [32], we wondered if this may be a secondary consequence of caspase activation. Consistently, upon CHK1 inhibition, Hoxb8-FL cells lacking BAX/BAK also stabilized p53 and showed significantly lower levels of γH2AX phosphorylation but no signs of PARP1 cleavage or cell death (Fig 1C). This suggests that in wild-type cells CHK1i treatment causes DNA damage, triggering a p53 response that precedes BCL2-regulated mitochondrial cell death involving caspase activation. Remarkably though, Hoxb8-FL cells derived from the bone marrow of p53−/− mice were still highly susceptible to cell death indicating a minor contribution of p53 target genes to apoptosis upon CHK1 inhibition (Figs 1A and EV1A, left panel). To obtain first mechanistic insight into this p53-independent cell death, we tested a series of Hoxb8-FL cells derived from mice lacking different pro-apoptotic “BH3-only” proteins that act as inducers of BAX and BAK activation in mitochondrial cell death [33,34]. Of note, loss of the BH3-only protein BIM provided some degree of protection when PUMA or NOXA was co-depleted (Fig EV1B and C). Together, this suggests that the BH3-only protein BIM, together with PUMA and NOXA mediate BAX/BAK activation upon CHK1 inhibition.

Interestingly, we also noted an altered cell cycle distribution in cells that failed to undergo cell death upon CHK1 inhibition. The majority of BCL2-overexpressing or BAX/BAK-deficient cells accumulated in the G1 fraction with a near complete loss of S-phase cells, indicating cell cycle arrest at the G1/S boundary when CHK1 function was inhibited and cell death blocked at the same time (Figs 1A and EV1A, right panel). Consistently, BAX/BAK-deficient cells showed a significant induction of p21 mRNA in response to CHK1 inhibition (Fig 1D). To corroborate this finding, we also performed population-doubling experiments in the presence or absence of CHK1 inhibitor. Indeed, cells overexpressing BCL2 or cells lacking BAX/BAK failed to proliferate when treated with CHK1i and showed near-constant cell numbers over time (Fig 1E).

Together, these findings underscore the importance of CHK1 for hematopoietic progenitor cell proliferation and survival by preventing BAX/BAK-mediated apoptotic cell death. Apoptosis seems to be initiated in response to DNA damage upon CHK1 inhibition but does not require p53. When cell death is blocked, these cells show signs of DNA damage and arrest the cell cycle at the G1/S boundary.

CHK1 inhibition kills primary mouse and human HSPCs via BCL2-regulated apoptosis

To get a first impression on how CHK1 inhibition affects primary HSPCs, we isolated Lin− Sca1+ cKit+ (LSK) cells, containing HSCs and MPPs, from the fetal liver of WT or Vav-BCL2 transgenic embryos or the bone marrow of adult mice. Sorted LSK cells from either source showed only modest cell death when treated with CHK1i in vitro but the cell death seen was blocked when BCL2 was overexpressed (Fig 2A, Appendix Fig S1A and B). This suggests that, compared to Hoxb8-FL cells, reduced proliferation rates in
Figure 1.

A. Cell cycle analysis for WT, p53−/−, Vav-BCL2, and Bax−/− Bak−/− cells treated with PF-477736 [1.5 µM] and DMSO ctrl.

B. Percentage of subG1 cells for WT, p53−/−, Vav-BCL2, and Bax−/− Bak−/− cells treated with PF [500 nM] and CHIR [100 nM] and CHIR [500 nM].

C. Western blot analysis showing cl. PARP1, p53, γH2AX, and HSP90 for WT and Bax−/− Bak−/− cells treated with CHIR-124 [500 nM].

D. p21 mRNA expression fold induction for WT, Bax−/− Bak−/− cells treated with CHIR, PF, and CHIR.

E. Cell number for WT, Vav-BCL2, and Bax−/− Bak−/− cells treated with PF and CHIR.
primary cells may impact on CHK1i sensitivity. Consistently, when we treated total fetal liver (FL) or total bone marrow cell cultures that both contain a substantial number of lineage-committed cycling hematopoietic progenitors with CHK1i, we observed a clear dose-dependent response, driving a significant portion of cells into apoptosis. Again, cell death was significantly reduced when BCL2 was overexpressed (Fig 2B and C). This indicates that actively cycling hematopoietic progenitors are more vulnerable to CHK1i, compared to LSK cells, suggesting that cell cycle rates define susceptibility to CHK1i.

To test whether these observations also hold true for human cells, we purified CD34+ HSPCs from the cord blood that reportedly express low-level CHK1 [35]. Indeed, a significant fraction of CD34+ cells died when treated with increasing doses of CHK1i in the presence of proliferation-inducing cytokines (Fig EV2A). This cell death was potently blocked by the pan-caspase inhibitor QVD, pointing toward mitochondrial cell death (Fig 3A). In line with our findings in mouse cells, cell death was reduced when BCL2 was overexpressed (Fig EV2A). This suggests that actively cycling hematopoietic progenitors are more vulnerable to CHK1i, compared to LSK cells, suggesting that cell cycle rates define susceptibility to CHK1i.

**Figure 1. CHK1 is an essential survival factor for Hoxb8-FL cells.**

A. Western blot of CHIR-treated Hoxb8-FL WT and Bax−/-Bak−/- cells using the indicated antibodies.

B. WT Hoxb8-FL cells were treated with CHIR-124 in the presence or absence of the pan-caspase inhibitor QVD. Cell death was assessed after 24 h using flow cytometry as in (A).

C. Western blot of CHIR-treated Hoxb8-FL WT and Bax−/-Bak−/- cells using the indicated antibodies.

D. WT and Bax−/-Bak−/- Hoxb8-FL cells were treated for up to 8 h with 500 nM CHIR, and p21 mRNA levels were compared to Hprt in response to CHK1i by real-time RT-qPCR. Bars represent means ± s.d. of independent experiments (n = 4–6), performed in duplicates.

E. 50,000 Hoxb8-FL cells of the indicated genotypes were seeded to assess cell growth in response to CHK1i inhibition. Cells were counted 48 h postseeding.

Data information: Asterisks indicate significant differences: *P < 0.05, **P < 0.01, ***P < 0.001 using unpaired Student’s t-test. Bars in (B) represent means ± s.e.m. (n = 2 biological and technical replicates per genotype). Bars in (E) represent means ± s.e.m. (n = 3 biological replicates per genotype).

Source data are available online for this figure.

**CHK1 is essential for establishing hematopoiesis in the fetal liver**

Our data indicate that CHK1 might be critical for the development of a functional hematopoietic system. To explore this genetically, we crossed mice harboring a conditional allele of Chk1 with a CRE-deleter strain specific for the hematopoietic system [36]. Deletion of Chk1 using Vav-driven CRE expression never resulted in viable mice at the time of weaning but caused hematopoietic failure and the death of Chk1−/− Vav-Cre embryos in utero (Fig 4A and B). The lack of red blood cells in the fetal liver of Chk1−/− Vav-Cre embryos at E13.5 was easily visible histologically (Fig 4C and D), pointing toward impaired erythropoiesis. Indeed, flow cytometric analysis revealed a decreased percentage of pro-erythroblasts (CD71+ cKit+) as well as erythroid progenitor (CD71+ CD45low) cells in the fetal liver of Chk1−/− Vav-Cre embryos and the erythrocytes present in these embryos appeared to be of primitive origin [37], judged on the lack of cKit expression on their cell surface (Fig EV3A and B). Furthermore, we could observe a clear reduction of all developmental stages of erythropoiesis in the fetal liver of Chk1−/− Vav-Cre embryos (Fig 4E).

Of note, we also failed to detect the typical LSK cell population enriched for HSPCs in the fetal liver. Within the Lin− fraction of cells, we found instead Sca1+ cells with a near 10-fold reduction of cKit expression (LSKlow cells), a phenomenon not seen in littermate controls (Fig 5A). Remarkably, the percentage of these LSKlow cells was actually increased about 5-fold leading to comparable overall LSK numbers compared to littermate controls (adding up LSKhi and LSKlow cells). In contrast, the fraction of Lin− LK cells, containing MPPs and more committed progenitors, was significantly reduced, both in relative and absolute terms. Although these cells also shifted into the LKlow fraction, their absolute number remained significantly decreased when adding up LKhi and LKlow cells (Fig 5A). This suggested that LK cells cannot survive or expand properly in the absence of Chk1.

To corroborate this phenotype further, we also performed colony formation assays in methyl cellulose. Neither sorted LSK cells nor total FL cells isolated from Chk1−/− Vav-Cre mice showed colony-forming potential (Fig 5B). A more detailed analysis of the LSK cell pool suggested loss of CD34+ Flt3− LT-HSC accompanied by a relative increase in CD34+ Flt3− ST-HSC. MPPs, characterized as CD34+ Flt3+, were found unchanged in percentage using this maker combination (Fig 5C).

Together, this suggests that failure in blood cell development and embryonic lethality in Chk1−/− Vav-Cre mice is potentially due to exhaustion of LT-HSC that actively cycle to colonize the fetal liver after migrating in from the AGM (aorta-gonad mesonephros) region [2,38]. Hematopoietic failure may be driven by the loss of ST-HSC, MPPs, or their immediate progeny that, based on our in vitro findings above, may undergo apoptosis in the absence of CHK1.

**DNA damage and subsequent cell death trigger compensatory proliferation and stem cell loss in the absence of Chk1**

Chemical inhibition of CHK1 induces DNA damage in cultured MPP-like cells and activates a p53-independent but mitochondrial cell death-dependent response (Fig 1). To explore whether this is also responsible for the phenotypes seen in vivo, we analyzed...
Figure 2. CHK1 inhibition kills primary murine HSPCs.  
A LSK (Lin− ScAl+ cKit+) cells of the indicated genotypes were isolated by cell sorting from the fetal liver at embryonic day E13.5 or the bone marrow of adult mice and treated for 48 h with PF-477736 (1.5 μM). Survival was assessed using Annexin V-staining and flow cytometry. Bars represent means ± s.e.m. from n = 6 wild-type and n = 3 Vav-BCL2 fetal liver LSK cells (left) and n = 3 bone marrow LSK cells (right).  
B, C WT and Vav-BCL2-derived E14.5 total fetal liver cells (B) or total bone marrow cells (C) were treated for 72 h (B) or up to 48 h (C) with different doses of CHK1i. Survival was assessed using Nicoletti staining and flow cytometry. Bars represent means ± s.e.m. (n = 3 biological replicates per genotype).  
Data information: Asterisks indicate significant differences: *P < 0.05, **P < 0.01, ***P < 0.001 using unpaired Student’s t-test.
cryosections from fetal livers by TUNEL-staining or FACS-sorted LSK cells to assess signs of DNA damage by intracellular staining for γH2A.X. Consistent with our findings in vitro, we found a strong increase in TUNEL-positive cells in E13.5 tissue sections (Fig 6A) and corresponding activation of ATR, detected by western in E13.5 total fetal liver lysates isolated from Chk1fl/-/C0 Vav-Cre embryos (Fig 6B). Moreover, DAPI-negative LSK and LK cells isolated by cell sorting from the fetal liver of Chk1fl/-/C0 Vav-Cre embryos showed a strong increase in γH2A.X phosphorylation (Fig 6C). The increased γH2A.X phosphorylation seen in these embryos provides a rational for the noted stem cell depletion (loss of G0 cells), due to increased proliferation of LSK and LK cells, forced into cycle in an attempt to compensate for the loss of erythroid cells or their progenitors.

Consistently, LSK and LK cells lacking CHK1 were devoid of Ki67-negative cells, indicating increased proliferation rates and simultaneously showed increased percentages of sub-G1 cells. Interestingly, the percentage of cells in S- or G2/M-phase was unaltered (Fig 6D and E). Together, this suggests that these cells accumulate DNA damage while cycling in the absence of CHK1, leading to apoptosis, which could explain the loss of LK cells seen. The increased death of LK cells appears to trigger increased LSK cell proliferation in order to maintain absolute cell numbers and to generate more LK cells that in turn eventually leads to HSC exhaustion.

To assess the contribution of cell death to the embryonic lethal phenotype, we overexpressed BCL2 in fetal liver stem cells by intercrossing Chk1fl/-/Vav-Cre with Vav-BCL2 transgenic mice or by co-deleting p53. Consistent with a failure of p53 loss to restore development of Chk1-deficient embryos [21,22], we also failed to detect restoration of hematopoiesis in Chk1fl/-/Vav-Cre p53/-/- embryos (Fig EV4A). Moreover, we also failed to observe a rescue of hematopoiesis upon BCL2 overexpression (Figs 7A and EV4A), indicating that even if cell death was blocked, these cells are unable to expand. Loss of p53 or overexpression of BCL2 had also no impact on the changes in cKit expression observed upon loss of Chk1 (Figs 7A and EV4B).

As seen before, we again noted a drop in LSK CD34+Flt3- LT-HSCs combined with an increase in the percentage of LSK CD34+Flt3- ST-HSCs and CD34+Flt3+ MPPs. BCL2 overexpression did not change the percentage of these cells (Fig 7B). Despite an observable trend toward an increase in surviving BCL2 transgenic LSKhi and LSKlo as well as LKhi cells (Fig EV4B), fetal liver cells
overexpressing BCL2 were again unable to give rise to colonies in methocult assays (Fig 7C). This suggests that HSPCs that may survive the loss of CHK1 in the presence of high BCL2 levels fail to expand and undergo cell cycle arrest, as these cells accumulate even more DNA damage when compared to Chk1fl/fl Vav-Cre cells (compare Figs 6C and EV4C). Consistently, Western analysis performed on E14.5 fetal liver cells confirmed that expression levels of CHK1 were drastically reduced in knockout embryos, as was the expression of Cyclin D (Fig 7D), suggesting that the residual fetal liver cells present were not cycling. Notably, BCL2 overexpression did not affect the loss of Cyclin D, confirming that when cell death is blocked, these cells still fail to thrive.

Taken together, our findings suggest that HSPCs depend on CHK1 to prevent the accumulation of DNA damage during cell cycle progression during fetal liver colonization and that in the absence of CHK1 these cells undergo apoptosis. Yet, when intrinsic apoptosis is impaired, cell cycle arrest prevents HSPC expansion as a second barrier to prevent subsequent mutational spread.

Figure 4. Deletion of Chk1 in HSC prevents fetal hematopoiesis.  
A Representative pictures of E13.5 and E18.5 embryos of the indicated genotypes. Scale bar E13.5 = 1 mm, E18.5 = 5 mm.  
B Quantification of fetal liver cell number at E13.5. Bars represent means ± s.e.m. (N = 4 for Chk1fl/fl, N = 3 for Chk1fl/+ Vav-Cre, and N = 4 for Chk1fl/fl Vav-Cre).  
C Representative pictures of isolated fetal livers at E13.5. Scale bar = 1 mm.  
D Representative H&E staining of fetal liver sections from E13.5 embryos. Black arrows indicate lack of erythroid cells in the blood vessels of Chk1fl/fl Vav-Cre fetal livers. Scale bar = 500 μm.  
E Single cell suspensions of fetal livers from Chk1fl/fl, Chk1fl/+ Vav-Cre, and Chk1fl/fl Vav-Cre embryos were stained with antibodies recognizing cKit, CD71, Ter119, or CD45 to assess primitive and definitive erythropoiesis by flow cytometry. Large “EryA” erythroblasts (CD71high Ter119high FSClow), smaller, more mature “EryB” erythroblasts (CD71high Ter119high FSClow); most mature erythroblast subset is EryC (CD71low Ter119high FSClow). Bars represent means ± s.e.m. ctrl N = 5 (pooled N = 4 Chk1fl/fl and N = 1 Chk1fl/+ Vav-Cre), N = 3 for Chk1fl/fl Vav-Cre.  
Data information: Asterisks indicate significant differences: *P < 0.05, **P < 0.01 using unpaired Student’s t-test.
To establish the role of CHK1 in adult hematopoiesis, we aimed to conditionally delete Chk1 in adult mice by taking advantage of tamoxifen (TAM)-inducible and hematopoiesis-restricted Cre transgene expression in Vav-CreERT2 mice [39].

To monitor recombination in hematopoietic cells by flow cytometry, we additionally introduced a CRE-reporter allele (mT/mG) in the ROSA26 locus that enables expression of membrane-targeted Tomato prior to and membrane-targeted GFP after CRE-mediated excision of a loxP flanked STOP cassette [40]. From these animals (mT/mG/C6 Chk1fl/fl), Hoxb8-FL cells were established and transduced with a retrovirus expressing CRE. GFP expression levels were followed over time, and GFP+ and Tomato + cells were sorted on day 2 after transduction.

** CHK1 deficiency causes stem cell loss in the fetal liver. **

A. Representative dot-plots of the LSK cell phenotype of Chk1fl/+ and Chk1fl/− Vav-Cre embryos observed in E13.5 fetal livers and relative distribution/absolute numbers of LKhi and LSKhi cells, as well as LKlow and LSKlow cells, found in the fetal liver on E13.5. Bars represent means ± s.e.m. N = 4 for Chk1fl/+ and N = 4 for Chk1fl−/− Vav-Cre.

B. Colony formation potential of FACS-sorted LSK cells (left panel, N = 4 for Chk1fl/+ and N = 5 for Chk1fl−/− Vav-Cre) and total fetal liver cells (right panel, N = 3 for Chk1fl/+ and N = 6 for Chk1fl−/− Vav-Cre) in methyl cellulose assays. Bars represent means ± s.e.m.

C. Flow cytometric analysis of LSKhi or LSKlow cells stained with antibodies specific for CD34 and Flt3 (N = 4 for Chk1fl/+ and N = 4 for Chk1fl−/− Vav-Cre), to discriminate LT- and ST-HSC from MPP within the LSK subset. Bars represent means ± s.e.m.

Figure 5. CHK1 deficiency causes stem cell loss in the fetal liver.

Data information: Asterisks indicate significant differences: *P < 0.05, **P < 0.01, ***P < 0.001 using unpaired Student’s t-test.
were found to lack CHK1 protein, but showed clear signs of DNA damage (Fig 8A). Similar findings were made when Hoxb8-FL cells from Chk1\textsuperscript{fl/+} mice were transduced with a retrovirus harboring a CRE-IREs-GFP cassette and GFP\textsuperscript{−} cells were sorted for Western blotting on day 3 (Fig 8B). Of note, GFP\textsuperscript{−} cells were rapidly lost over time (Fig 8A), suggesting rapid cell death in the absence of CHK1.
Yet, Western analysis is of limited sensitivity and PCR analysis amplifying the conditional allele still scored positive in FACS-sorted GFP+ cells, indicating the presence of cells that had retained at least one functional Chk1 allele (Appendix Fig S2).

Next, compound mutant mice were treated with tamoxifen by oral gavage for 5 days and reporter activity was monitored in the blood 2 or 9 days later (day 7 and day 14). In general, tamoxifen treatment led to a reduction in total white blood cell (WBC) counts, affecting lymphoid and myeloid cells alike, but this was not related to the genotype. In addition, mice carrying the conditional Chk1 allele presented with a transient drop in platelet number on day 7 that was no longer visible on day 14 of analysis (Fig EV5).

Tracing CRE-mediated recombination by PCR and GFP expression in primary and secondary hematopoietic organs revealed that up to 25% of myeloid cells in the peripheral blood were GFP+ but only about 10% of T or B cells showed reporter expression (Fig 8C and D, Table EV1, Appendix Fig S3). In the bone marrow, the percentage of LSK and NK cells was comparable between genotypes (Fig 8E) and an average of 40% of LSK and NK cells was found GFP+ indicating deletion of Chk1 by day 15 (Fig 8F; Table EV1). Yet, with the exception of a transient reduction of GFP+ LK cells on day 8 in Chk1fl/+ Vav-CreERT2 mice (Fig 8F), suggesting increased vulnerability, no significant difference was seen between the genotypes. Within the GFP-positive fraction, the distribution of Lin− cells as well as that of NK or LSK cells was again comparable between genotypes, suggesting that timed deletion of Chk1 might be well-tolerated in bone marrow-resident LSK and NK cells of adult mice (Table EV1).

Of note, the percentage of GFP+ cells gradually decreased with maturation stage, but this was seen in both genotypes tested, demonstrating only the gradual and time-dependent turn-over of the hematopoietic system (Table EV1). Consistently, in the bone marrow, up to 37% of IgM AA4.1+ pro/pre-B and 27% of IgM AA4.1+ naïve B cells, but only 2% of recirculating IgM+ D− B cells were found to be GFP+ on day 15. Accordingly, only about 13% of splenic IgM+ D− B cells were GFP+, indicating CRE deletion, while up to 30% myeloid cells in the spleen or bone marrow switched from Tomato to GFP expression (Table EV1). The percentage of GFP-positive thymocytes carrying the conditional Chk1fl/fl allele was ranging between 12 and 22% on day 15 but only about 3% of all mature CD4+ or CD8+ T cells expressed GFP in the periphery (Table EV1, Appendix Fig S3).

Remarkably, however, within the GFP+ subset that has activated CRE recombinase, the distribution of T cells, B cells, and myeloid cells was always comparable between genotypes, suggesting that loss of CHK1 did not perturb leukocyte homeostasis in vivo, at least not within our observation period of 15 days. Alternatively, GFP− cells may not have deleted both Chk1 alleles, despite recombining the reporter allele. To monitor deletion at the protein level, GFP+ and Tomato+ fractions were sorted from the bone marrow on day 8 and the thymus on day 15 after the first oral gavage. Bone marrow samples from three animals were pooled to obtain cell numbers suitable for Western analysis (Fig 8G). Remarkably, while the expression of CHK1 was significantly reduced in GFP+ bone marrow cells on day 8, GFP+ and Tomato+ thymocytes showed highly comparable CHK1 protein levels on day 15 after the first administration of tamoxifen (Fig 8H). This suggests that only cells that manage to maintain CHK1 expression are able to reach the thymus, and together, these findings indicate that CHK1 expression is essential for the maintenance of a functional hematopoietic system in the adult.
Figure 7.
Figure 8.
Discussion

HSC are responsible for the supply of blood cells throughout our lifetime. Therefore, it is essential to control their stemness in response to proliferative cues to avoid stem cell exhaustion driving hematopoietic failure and to prevent accumulation of DNA damage or mutations that might contribute to malignant disease with age. CHK1 is a key regulator of DNA-replication fidelity and the G2/M transition upon DNA damage, critical in early embryogenesis and meanwhile a recognized target in cancer therapy [11,41]. Yet, the impact of CHK1 loss or inhibition on normal hematopoiesis remains largely unknown.

We could recently show that human Burkitt’s lymphoma and pre-B ALL cell lines, similar to primary pre-B and mature B cells from mice, die an apoptotic cell death controlled by the BCL2 family when treated with CHK1 inhibitors [24]. Similarly, as reported here, MPP-like Hoxb8-FL cells undergo mitochondrial apoptosis when treated with CHK1. This death is clearly BAX/BAK dependent and can be delayed by BCL2 overexpression (Figs 1 and 2). Remarkably, despite the induction of DNA damage and subsequent p53 stabilization, these cells are not protected from death by loss of p53. This suggests that NOXA and PUMA, two recognized pro-apoptotic p53 target genes that act upstream of BAX/BAK [42], may only play a limited role in this apoptotic response. Instead, double depletion of Bim and Noxa (or to a minor extent Bim and Puma) could delay cell death similar to BCL2-overexpression in vitro (Fig EV1); however, the precise mechanism of BAX/BAK activation in response to CHK1 inhibition remains to be investigated in detail. Of note, the mode of cell death seems to be conserved in human CD34+ HSPCs (Fig 3).

**Figure 8. Acute depletion of Chk1 in the hematopoietic system leads to cell loss in vitro and retention of CHK1 expression in vivo.**

A Three independent Chk1fl/fl mT/mG (colored) and mT/mG (grey) Hoxb8-FL progenitor cell lines were transduced with a retroviral construct carrying Cre (pMIP-CRE-IRES-PURO) and monitored over time for GFP expression. Shown here are three technical replicates per genotype. Additionally, Chk1fl/fl mT/mG Hoxb8-FL progenitor cells were FACs-sorted for GFP+ and dsRED+ cells 48 h after transduction with the Cre-construct. Sorted cells were processed for Western blotting using the indicated antibodies.

B Chk1fl/fl Hoxb8-FL progenitor cells were transduced with a retroviral construct carrying Cre and GFP (pMIG-CRE-IRES-GFP). Cells were FACs-sorted 72 h after transduction with the retroviral construct and processed for Western blotting using the indicated antibodies.

C Percentage of GFP+ cells indicative for CRE expression and recombination in the peripheral blood after tamoxifen administration by gavage (5 × 2 mg, 200 µl/mouse, daily). Bars represent means ± s.e.m. (Day 0 N = 9/10, WT/Chk1fl/fl; Day 7 N = 8/7, Day 14 N = 3/3).

D Quantification of Chk1-del PCR-product enrichment in DNA from GFP+ vs. Tomato+ bone marrow cells sorted on day 8 after first TAM administration. Transgenic Cre levels were quantified in parallel for reference. Bars represent means ± s.e.m. from n = 5 mT/mG Vav-CreERT2 Chk1fl/fl mice.

E, F (E) Percentage of living LK or LSK cells and (F) percentage of GFP+ LK or LSK cells found in the bone marrow of mT/mG Vav-CreERT2 (WT) and mT/mG Vav-CreERT2 Chk1fl/fl (Chk1fl/fl) mice on day 8 or 15 after first TAM administration. Bars represent means ± s.e.m. (Day 8 N = 8/8, WT/Chk1fl/fl, Day 15 N = 7/8).

G GFP+ (CRE) and Tomato+ (CRE-) total bone marrow cells were sorted on day 8 after first TAM administration and processed for Western blot using the indicated antibodies. Sorted cells from three animals—mT/mG Vav-CreERT2 (WT) and mT/mG Vav-CreERT2 Chk1fl/fl (Chk1fl/fl)—were pooled per lane.

H Thymocytes of the indicated genotypes were sorted based on GFP+ and Tomato+ on day 15 after the first TAM administration for Western analysis using the indicated antibodies.

Data information: Asterisks indicate significant differences: *P < 0.05, **P < 0.01, ***P < 0.001 using unpaired Student’s t-test. Source data are available online for this figure.

In support of this notion, we could detect only ~6% cKit+ cells in Chk1fl/fl Vav-Cre fetal liver at E13.5 compared to more than 40% in littermate controls (Fig EV4). Although cKit cannot be used as a general marker for dHSC and their progeny, as it is present on a variety of other cell types, it can be used to discriminate primitive HSC (pHSC) as well as primitive erythrocytes from dHSC and definitive erythrocytes, as the former lack cKit, as reviewed in Ref. [2]. Furthermore, it was shown that only cKit+ cells, but not cKitlow or cKit- cells from the E11.5 AGM region or the fetal liver, can reconstitute lethally irradiated mice confirming that definitive hematopoiesis relies on the SCF receptor, cKit [43]. Together, this suggests that loss of CHK1 using Vav-Cre, activated as early as on day E11.5 [44], results in the loss of definitive hematopoiesis in the fetal liver and that the blood cells we can detect in Chk1fl/fl Vav-Cre embryos are of primitive hematopoietic ancestry.

Interestingly, LSK cells isolated from the fetal liver did not massively die in culture when treated with the CHK1 inhibitor while total fetal liver cells did die in a dose-, time-, and BCL2-dependent manner (Fig 2), suggesting that loss of CHK1 dominantly affects the survival of actively cycling HSPCs. This may be explained by the fact that all these cells have a higher proliferative index compared to LSK cells. An alternative explanation would be the lack of CHK1 expression in fetal liver-resident LSK cells, rendering them insensitive to CHK1 inhibitors. Indeed, mRNA expression analysis showed lowest levels of Chk1 mRNA in resting bone marrow LSK cells but higher levels in fetal liver LSKs and mobilized LSKs or MPPs [29], as well as increased CHK1 protein in expanding human CD34+ HSPCs [35]. Moreover, mobilized LSK cells showed clear signs of replication stress-associated CHK1 activation and hallmarks of DNA damage [30], indicating the need for CHK1 to deal with replication stress in cycling HSPCs that would otherwise trigger apoptosis. This notion is further supported by the fact that we observed a 7-fold decrease
in total fetal liver cell number (Fig 4B) in the absence of CHK1 but normal absolute numbers of LSK cells (Fig 5A). It seems that in the absence of CHK1-mediated cell cycle control, LT-HSC lose self-renewal potential and exhaust (Fig 5) because they are recruited into the pool of transient amplifying ST-HSC and MPP. These cells then arrest their cell cycle in the presence of accumulating DNA damage when unable to die. Indeed, we could observe the induction of cell cycle arrest and p21 mRNA when we tested BCL2-overexpressing or BAX/BAK-deficient Hoxb8-FL cells in response to CHK1i that cannot undergo apoptosis (Fig 1). Together, this might explain why overexpression of BCL2 in fetal liver HSPCs fails to rescue hematopoiesis in the absence of CHK1 (Fig 7), despite protecting HSPCs from cell death in vitro (Fig 2).

Similar to what we have noted in MPP-like cells and fetal liver cell cultures, deletion of CHK1 in the small intestine, using CYP1A1 promoter to drive CRE expression in AhCre mice, leads to p53-independent apoptosis due to massive DNA damage. Remarkably, the GI tract can be restored in these mice from stem cells that fail to delete Chk1 [45], a phenomenon not seen in Chk1+/- Vav-Cre embryos but clearly visible in animals where we attempted conditional deletion of CHK1 (Fig 8). In this case, reporter activity failed to faithfully read out target gene deletion, as noted by others in various settings [46], suggesting essential roles for CHK1 also in adult hematopoiesis. In line with these observations, developing mammary epithelial cells and early thymocytes do undergo cell death when CHK1 is deleted using WAP-Cre or Lck-Cre, respectively [25,47]. Furthermore, deletion of CHK1 in B-cell progenitors using Mbi-Cre blocks B-cell development at the pro-B-cell stage in the bone marrow [24]. Of note, neither B-cell nor T-cell development could be restored by BCL2 overexpression, indicating concomitant induction of cell cycle arrest. This response was documented in cycling pre-B cells unable to undergo apoptosis upon CHK1i treatment [24]. Collectively, this suggests that deletion of CHK1 is lethal for cycling cell types, with the notable exception of chicken DT40 B lymphoma cells [48]. Consistently, adult hepatocytes are unaffected by loss of CHK1, most likely as homeostatic hepatocyte proliferation is minimal [49,50].

Of note, deletion of other components of the cell cycle network controlling faithful chromosome segregation and safe passage through M-phase give phenotypes similar to those caused by CHK1i treatment. This response was documented in cycling pre-B cells unable to undergo apoptosis upon CHK1i treatment [24]. Collectively, this suggests that deletion of CHK1 is lethal for cycling cell types, with the notable exception of chicken DT40 B lymphoma cells [48]. Consistently, adult hepatocytes are unaffected by loss of CHK1, most likely as homeostatic hepatocyte proliferation is minimal [49,50].

Mice

Animal experiments were performed in accordance with Austrian legislation (BMWF: 66-011/0106-WF/3b/2015) and in agreement with the animal ethics committee of the Medical University of Innsbruck. The generation and genotyping of Chk1+/- Vav-Cre, BCL2+/- Vav-Cre, and Vav-CRE-ERT2 mice have been described [36,39,48,57,58,59]. All mice were maintained or backcrossed on a C57BL/6N genetic background. Mice were housed in ventilated cages with nesting material and were maintained on a 12:12-h light:dark cycle. If not stated differently, mice were analyzed at the age of 8–16 weeks. 200 mg tamoxifen was dissolved in 500 μl 100% EtOH and subsequently mixed with 19.5 ml sterile filtered sunflower oil while intensive vortexing. 1 ml aliquots were frozen at −20°C. Prior use, aliquots were thawed at 37°C. Each mouse received 10 mg tamoxifen via gavage (5 × 2 mg/200 μl/day). Cohort A: 12 mice (three experimental mice and three controls analyzed at days 8 and 15 each), Cohort B: 19 mice (five experimental mice and five controls analyzed at day 8; five experimental mice and four controls analyzed at day 8). Semi-blinded cohorts were used meaning it was known that, e.g., three experimental and three control mice were within the group, but the genotype of each individual mouse was not known for the experimenter. Post-mortem mice were re-genotyped via PCR to ensure the correct genotype.

Cell culture

All murine cells were cultured in RPMI-complete medium: RPMI-1640 medium (Sigma-Aldrich, R0883), supplemented with 10% FCS (Gibco, 10270-106), 2 mM l-glutamine (Sigma, G7513), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma, P0781), and 50 μM 2-mercaptoethanol (Sigma, M3148). Hoxb8-FL cells were cultured in
RPMI-complete supplemented with 1 μM β-estradiol and 5% supernatant of FLT-3L expressing B16-melanoma cells. Primary murine bone marrow cells, fetal liver cells, or FACS-sorted bone marrow or fetal liver-derived LK or LSK cells were cultured in RPMI-complete media, supplemented with 1 mM sodium pyruvate (Thermo Fisher, 11360070), 1% non-essential amino acids (Thermo Fisher, 11140035), 5% supernatant of FLT-3L expressing B16 melanoma cells, and 2% supernatant of SCF-producing CHO (Chinese hamster ovary) cells. Human cord blood-derived CD34+ HSPCs were cultured in StemPro®-34 SFM 1× serum-free medium (Gibco™; 10639011) supplemented with 10% ES-FCS (Gibco™; 16141061), and human SCF (100 ng/ml, ImmunoTools, 11343325), FLT-3L (100 ng/ml; ImmunoTools 11340035), TPO (50 ng/ml ImmunoTools, 11344863), and IL-3 (20 ng/ml, ImmunoTools 11340035) cytokines.

**Generation of Hoxb8-FL cells**

Fresh bone marrow suspension cells from adult mice were cultivated (1/10th of the cells flushed from 1 tibia and 1 femur) for 2 days in Opti-MEM® (Gibco, Cat. 31985070) supplemented with 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μM 2-mercaptoethanol, 10 ng/ml IL-3 (Lot #120948 C2013, PeproTech), 20 ng/ml IL-6 (Lot #090850 A3013, PeproTech), and 2% supernatant of SCF-producing CHO (Chinese hamster ovary) cells. Human cord blood-derived CD34+ HSPCs were cultured in StemPro®-34 SFM 1× serum-free medium (Gibco™; 10639011) supplemented with 10% ES-FCS (Gibco™; 16141061), and human SCF (100 ng/ml, ImmunoTools, 11343325), FLT-3L (100 ng/ml; ImmunoTools 11340035), TPO (50 ng/ml ImmunoTools, 11344863), and IL-3 (20 ng/ml, ImmunoTools 11340035) cytokines.

**Reagents**

PF-477736 (Selleckchem S2904), CHIR-124 (Selleckchem S2683), QVD (SML0063, Sigma), DMSO (D5879, Sigma), and tamoxifen (Sigma, T5648).

**Flow cytometry and cell sorting**

Flow cytometric analysis or cell sorting of single cell suspensions generated from bone marrow or fetal liver was performed on an LSR Fortessa or a FACS-Aria III, respectively (both BD), and analyzed using FlowJo® v10 software. Antibodies used were as follows: eBioscience lineage-depletion antibodies (B220-bio RA3-6B2, Ter119-bio TER-119, CD3e-bio 145-2C11, CD11b-bio M1/70, Gr-1-bio RB6-8C5), NK1.1-bio (PK136, BioLegend), Sca1-APC (D7, BioLegend), Sca1-PE (D7, BioLegend), cKit-PE/Cy7 (2B8, BioLegend), cKit-PerCP (2B8, BioLegend), cKit-PerCP-Cy5.5 (2B8, BioLegend), cKit-BV421 (2B8, BioLegend), CD48-APC (HM48.1, BioLegend), CD150-PE/Cy7 (TC15-12, BioLegend), CD34-eFluor450 (RAM34, eBioscience), Flt3-PE (A2F10, eBioscience), CD45-PE (30-F11; BioLegend), CD71-APC (R17217, eBioscience), B220-FTC (RA3-6B2, BioLegend), B220-APC/eFl780 (RA3-6B2, eBioscience), B220-PE (BD RA3-6B2), B220-PerCP-Cy5.5 (RA3-6B2, BioLegend), CD19-BV605 (6D5, BioLegend), IgM-APC (RMM-1, BioLegend), IgM-FTC (BD II/41), IgM-eF450 (eB121-15F9, eBioscience), IgD-PerCP-Cy5.5 (11-26c2a, BioLegend), TCRβ-BV605 (BD, H57-597), TCRβ-FTC (H57-597, eBioscience), CD4-eF450 (GK1.5, eBioscience), CD8-alex487 (BD, 557082), Mac1-APC (M1/70, eBioscience), CD25-PE (PC61, BioLegend), CD93-PE/Cy7 (AA4.1, eBioscience), NK1.1-APC (PK136, BioLegend), Ter119-PerCP/Cy5.5 (TER-119) Annexin V-FITC (Lot: B206041, BioLegend), and Annexin V-eF450 (Lot: E11738-1633, eBioscience).

**Nicoletti staining**

Cells were fixed in 1 ml 70% ethanol while vortexing and stored at −20°C for a minimum of 60 min. Prior antibody staining, cells were washed twice (800 g, 5 min) with 2 ml PBS to remove ethanol. After RNase A (Sigma) digestion (100 mg/ml in PBS, 30 min at 37°C), cells were stained with propidium iodide (40 μg/ml) and the percentages of sub-G1, G1, S, and G2/M cells were monitored by flow cytometry.

**Intracellular staining for γH2A.X**

Cells were fixed in ethanol and stored at −20°C. After two washes with PBS, cells were incubated for 15 min in PBS + 0.25% Triton X-100 (Sigma) on ice for permeabilization. Cells were incubated for 60' with anti-Human/Mouse phospho-H2A.X S139 mAb PerCP-eFluor® 710 (clone CR55733, eBioscience). Cells were washed in PBS 1%BSA. DAPI (200 ng/ml) was used for DNA content analysis.

**Intracellular Ki67 staining**

10^6 bone marrow cells were incubated for 30 min at 4°C with the primary antibody mix: lineage-biotin antibodies for B220, CD3, Gr1, Mac1, NK1.1, Ter119, plus antibodies recognizing Sca1-APC or cKit-PE/Cy7 (all 1/100 in PBS + 10%FCS, 50 μl/tube). Cells were washed with 2 ml PBS; then, cells were stained with the secondary antibody mix: streptavidin-PerCP/Cy5.5 (1/100 in PBS + 10%FCS, 50 μl/tube). Cells were washed twice with 2 ml PBS. Cells were fixed and permeabilized using the reagent from the APC-BrDu Flow-Kit (BD, Vienna, Austria), according to the manufacturer's recommendation: Cytofix/Cytoperm, 10' on ice, 100 μl/tube, Perm/Wash, 1 ml/tube (400 g, 5'), Cytofix/Cytoperm-PLUS, 10' on ice, 100 μl/ml/tube, Perm/Wash, 1 ml/tube (400 g, 5'), Cytofix/Cytoperm, 5' room temperature, Perm/Wash, and 1 ml/tube (400 g, 5'). Then, cells were incubated for 30' on ice with Ki67-alexa488 (16A8, BioLegend), 1/100 in Perm/Wash buffer, and 50 μl/tube. Cells were washed twice with Perm/Wash buffer and 1 ml/tube (400 g, 5'), 300 μl DAPI (final concentration 200 ng/ml) diluted in PBS + 10% FCS was added, and cells were analyzed on a flow cytometer.

**Viability assay**

Cells were co-stained with Annexin V-FITC, Annexin V-Alexa647, or Annexin V-Pacific blue (BioLegend) 1:1,000 in Annexin V binding buffer (BD) and 7-AAD (1 μg/ml, Sigma). Cell death was analyzed by subsequent flow cytometric analysis.

**Isolation of CD34+ cells**

Human cord blood was collected immediately following cesarean births after informed consent of the parents and approval of ethical committee of University Hospital Freiburg, Germany. After Ficoll density gradient-based separation of mononuclear cells, CD34+ cells were isolated with MACS technology (Miltenyi Biotec). The purity
of CD34⁺ cells was generally greater than 90% as determined via FACS. The purified cells were then frozen in CryoStor CS 10 (Merck, C2874) and stored in liquid nitrogen for later use. After thawing, cells were cultured at a density of 2.5 × 10⁶ cells/ml overnight. StmPro™-34 SFM 1× serum-free medium (Gibco™, #10639091 supplemented with 10% ES-FBS (Gibco™, # 16141061) and human SCF (100 ng/ml, ImmunoTools, 11343325), FLT-L (100 ng/ml; ImmunoTools, 11343305), TPO (50 ng/ml ImmunoTools, 11344863), and IL-3 (20 ng/ml, ImmunoTools, 11340035). For colony-forming assays, MethoCult™ SF H4436 medium (Stem Cell Technologies) was used. Cells were added with or without CHK1 inhibitors at a density of 10² cells/ml/35 mm cell culture dish and incubated for 10 days. Afterward, colony counts and total cell counts were conducted. Lentiviruses GFP co-expressing pLeGO-iG lentiviral vector, Vsv.g-envelope, and Gag/Pol plasmids were utilized for the production of BCL-2 expressing viruses. As described in Ref. [59], HEK293T cells were used for viral packaging. CD34⁺ cells were incubated with lentiviruses in the presence of serum-free medium with cytokines for 48 h (MOI = 10 per day).

Gene expression

RNA was isolated from snap-frozen FACS-sorted or in vitro cultivated HoxB8-FL cells using the Qiagen RNeasy Mini Kit (74104) and the RNase-Free DNase Set (79254) according to the manufacturer’s instructions. For each sample, hundred nanograms of RNA was reverse-transcribed to cDNA using the iScript cDNA Synthesis Kit (1708890) according to the manufacturer’s instructions. For qRT-PCR with the StepOnePlus System (Applied Biosystems), we used the 2× SYBR Green qPCR Master Mix from BioTool (B21203). Expression levels of p21 mRNA were normalized to the housekeeping gene Hprt. Primers used were as follows (5'-3'): p21_Fw AAT TGG AGT CAG GCG CAG AT, p21_Rv GTC ATG CCG ACC CGC AGT C, Hprt_Fw GTC ATG GCC CCC AGC AGT C, Hprt_Rv GTC CTT CCA TAA TAG TCC ATG AGG AAT AAA C.

Immunoblotting

Cells were lysed in 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na₃VO₄, 1 mM PMSF, one tablet protease inhibitors (EDTA free, Roche) per 10 ml, and 30 μl/ml DNaseI (Sigma-Aldrich) and analyzed by Western blot analysis. For detection of proteins by chemoluminescence (Advansta, K-12049-D50), a mouse anti-CHK1 (CS 2360, 2G1DS), rabbit anti-γH2A.X (CS 2577), rabbit anti-p53 (Santa Cruz sc-6243), rabbit anti-PARP1 (CS 9542), mouse anti-CycD3 (BD 554195), mouse anti-hBCL2 (clone Si00), rabbit anti-ATR-pSer428 (CS 2853), or rabbit anti-actin (CS 4967) was used. Goat anti-rabbit Ig/HRP (Dako, P0448) or rabbit anti-mouse Ig/HRP (Dako, P0161) was used as secondary reagent.

Histology

For fixation and embedding E13.5, embryos were transferred to 4% paraformaldehyde (PFA in PBS) for fixation. Embryos were washed with 1 mM TBS (50 mM Tris-Cl, pH 7.5 150 mM NaCl) 2 × 15 min, 2 × 30 min, 70% EtOH, 80% EtOH, and 90% EtOH each for 30 min followed by 3 × 60 min incubation with 100% EtOH for dehydration. To remove the ethanol, embryos were incubated in methyl benzoate for a minimum of 24 h. Embryos were incubated for 2 × 30 min with benzol, then with a 1:1 benzol-paraffin mixture at 60°C, and then in molten paraffin at 60°C. After positioning the embryos, paraffin dishes were placed on a cooling plate to enable a quick and homogenous hardening of the paraffin. Histology blocks were cut sagittal with a rotation microtome (ReichertJung, Leica 2040) and sections pressed on silanized glass slides.

TUNEL assay

Slides were incubated 3 × 10 min with xylene, 3 × 5 min with 96% EtOH, 5 min with 70, 50, 30% EtOH, and PBS for rehydration. Slides were re-fixed with 4% PFA in PBS for 20 min, washed with PBS for 30 min, and permeabilized using 0.1% Triton X-100, 0.1% sodium citrate in a.d. for 2 min on ice. Slides were dehydrated after another washing step with TBS using 5-min incubation with 50, 70, and 96% EtOH, rinsed in chloroform, and then dried for 1 h at 37°C in a moist chamber. The TUNEL reaction was carried out by incubating sections with 15 μl of 0.6 μM FITC-labeled 12-dUTP (Roche, Basel, Switzerland), 60 μM dATP, 1 mM CaCl₂, and terminal deoxynucleotidyl transferase buffer (30 mM Tris, pH 7.2, 140 mM sodium cacodylate), and 25 units of terminal deoxynucleotidyl transferase (Roche, Basel, Switzerland) for 1 h at 37°C and covered with a plastic coverslip. The reaction was stopped by the addition of 10 mM Tris/1 mM EDTA, pH 8.0, for 5 min. Sections were washed twice in TBS before adding DAPI (2 μg/ml, in TBS, 40 μl/slide) for 10 min. Slides were washed twice with PBS and mounted in Mowiol® 40-88 (Sigma-Aldrich; 15 μl/slide).

Statistical analysis

Statistical analysis was performed using unpaired Student’s t-test or analysis of variance (ANOVA) for multiple group comparisons using Prism GraphPad software.

Expanded View for this article is available online.

Acknowledgements

We are grateful to K. Rossi, C. Sorato, I. Gaggl, M. Fischer, J. Vier, and J. Blitz for excellent technical assistance or animal care. We also thank J. Adams, S. Lowe, S. Elledge, and T. Mak for sharing mouse models. This work was supported by the FWF-funded Doctoral College “Molecular Cell Biology and Oncology” (W1101) and grant # I3271, “New insights into the BCL2 family” (FOR2036) and by the Deutsche Forschungsgemeinschaft (Grant HA2128/19-1). F. Schuler was supported by a Doc-fellowship from the Austrian Academy of Science (OAW) as well as intramural funding from the Medical University of Innsbruck (MUI-Start-2018-01-006).

Author contributions

FS performed experiments, analyzed data, prepared manuscript and figures; SA performed experiments with CD34⁺ HSPCs; ME supervised experiments with CD34⁺ HSPCs; GH provided HoxB8-FL cells and related expertise; CM performed histological analysis; and AV designed research, analyzed data, wrote paper, and conceived study.

Conflict of interest

The authors declare that they have no conflict of interest.
References

1. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang C, Huang G, Di Gian-domenico S, Lee JM, Deblasio A et al (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4: 37 – 48
2. Medvinsky A, Rybtsov S, Taoudi S (2011) Embryonic origin of the adult hematopoietic system: advances and questions. Development 138: 1017 – 1031
3. Haas S, Trumpf A, Milsom MD (2018) Causes and consequences of hematopoietic stem cell heterogeneity. Cell Stem Cell 22: 627 – 638
4. Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, Tsukui H, Ema H, Kamiio T, Katoh-Fukui Y et al (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21: 843 – 851
5. Sugiyma T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the hematopoietic stem cell pool by CXCL12-CXCXR5 chemokine signaling in bone marrow stromal cell niches. Immunity 25: 977 – 988
6. Fujisaki J, Wu J, Carlson AL, Silberstein L, Puthepi T, Larocca R, Larocca R, Gao W, Saito Ti, Lo Celso C et al (2011) In vivo imaging of Treg cells providing immune privilege to the hematopoietic stem-cell niche. Nature 474: 216 – 219
7. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo MM, Karlsson S, Iwama A, Nakauchi H (2011) Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147: 1146 – 1158
8. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinuk U, Duchosal MA, Trumpf A (2009) IFNalpha activates dormant hematopoietic stem cells in vivo. Nature 458: 904 – 908
9. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA (2010) Quiescent hematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature 465: 793 – 797
10. Ma CX, Janetka JW, Piwnica-Worms H (2011) Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17: 88 – 96
11. Zhang Y, Hunter T (2014) Roles of Chk1 in cell biology and cancer therapy. Int J Cancer 134: 1013 – 1023
12. Burgess RC, Misteli T (2015) Not all DDRs are created equal: non-canonical DNA damage responses. Cell 162: 944 – 947
13. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288: 1425 – 1429
14. Reinhardt HC, Adljan AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175 – 189
15. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501 – 1505
16. Booher RN, Holman PS, Fattaey A (1997) Human Mrt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 272: 22300 – 22306
17. Heald R, McLaughlin M, McKeon F (1993) Human weel maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 74: 463 – 474
18. Sheih SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases chk1 and csk1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289 – 300
19. Roos WP, Kaina B (2013) DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 332: 237 – 248
20. David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE et al (2016) CHK1 as a therapeutic target to bypass chemoresistance in AML. Sci Signal 9: ra90
21. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev 14: 1448 – 1459
22. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, Ikedo K, Nakayama K, Nakashima M, Nakayama K (2000) aberrant cell cycle checkpoint function and early embryonic death in Chk1-/- mice. Genes Dev 14: 1399 – 1447
23. Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM (2010) Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One 5: e8581
24. Schuler F, Weiss JG, Lindner SE, Lohmuller M, Herzog S, Spiegel SF, Menke P, Geley S, Labi V, Villunger A (2017) Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis. Nat Commun 8: 1697
25. Zaugg K, Su WY, Reilly PT, Moolani Y, Cheung CC, Hakem R, Hirao A, Liu Q, Elledge SJ, Mak TW (2007) Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci USA 104: 3805 – 3810
26. Trumpf A, Essers M, Wilson A (2010) Awakening dormant hematopoietic stem cells. Nat Rev Immunol 10: 201 – 209
27. Walter D, Lier A, Geiselhart A, Thalheimer F, Hunscha S, Sobotta MC, Moehrle B, Brocks D, Bayindir I, Kaschutnig P et al (2015) Exit from dormancy provokes DNA-damage-induced attrition in hematopoietic stem cells. Nature 520: 549 – 552
28. Matatail KA, Jeong M, Chen S, Sun D, Chen F, Mo Q, Kimmel M, King KY (2016) Chronic infection depletes hematopoietic stem cells through stress-induced terminal differentiation. Cell Rep 17: 2584 – 2595
29. Beerman I, Seita J, Inlay MA, Weissman IL, Rossi DJ (2014) Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 15: 37 – 50
30. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diaoati ME, Ugarte F, Forsberg EC et al (2014) Replication stress is a potent driver of functional decline in ageing hematopoietic stem cells. Nature 512: 198 – 202
31. Redecke W, Wu R, Zhou J, Finkelstein D, Chaturvedi V, High AA, Hacker H (2013) Hematopoietic progenitor cell lines with myeloid and lymphoid potential. Nat Methods 10: 795 – 803
32. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM (1998) Mitochondrial apoptosis for vertebrate development and postnatal tissue homeostasis. Genes Dev 12: 2151 – 2156
33. Carrassa L, Montelatici E, Lazzari L, Zagrossi S, Simone M, Broggini M, Damia G (2010) Role of Chk1 in the differentiation program of hematopoietic stem cells. Cell Mol Life Sci 67: 1713 – 1722
34. de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, Norton T, Williams K, Rodenck K, Potocnik AJ et al (2003) Transgenic mice with...
hematopoietic and lymphoid specific expression of Cre. Eur J Immunol 33: 314 – 325
37. England SJ, McGrath KE, Frame JM, Palis J (2011) Immature erythroblasts with extensive ex vivo self-renewal capacity emerge from the early mammalian fetus. Blood 117: 2708 – 2717
38. Medvensky A, Dzierzak E (1996) Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86: 897 – 906
39. Herold MJ, Stuchbery R, Merino D, Willson T, Strasser A, Hildeman D, Bouillet P (2014) Impact of conditional deletion of the pro-apoptotic BCL-2 family member BIM in mice. Cell Death Dis 5: e1446
40. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L (2007) A global double-fluorescent Cre reporter mouse. Genesis 45: 583 – 605
41. Otto T, Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17: 99 – 115
42. Villunger A, Michalak EM, Coutsou L, Mullauer F, Bock G, Außerlechner MJ, Adams JM, Strasser A (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036 – 1038
43. Sanchez MJ, Holmes A, Miles C, Dzierzak E (1996) Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. Immunity 5: 513 – 525
44. Bustelo XR, Rubin SD, Suen K-L, Carrasco D, Barbacid M (1999) Developmental expression of the vau protooncogene. Cell Growth Differ 4: 297 – 308
45. Greenow KR, Clarke AR, Jones RH (2009) Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensatory repopulation. Oncogene 28: 1443 – 1453
46. Becher B, Waisman A, Lu LF (2018) Conditional gene-targeting in mice: problems and solutions. Immunity 48: 835 – 836
47. Lam MH, Liu Q, Edlejde SJ, Rosen JM (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6: 45 – 59
48. Zachos G, Rainey MD, Gillespie DA (2003) Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 22: 713 – 723
49. Fujisawa T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043 – 1047
50. Pandit SK, Westendorp B, de Bruin A (2013) Physiological significance of polyploidization in mammalian cells. Trends Cell Biol 23: 556 – 566
51. Ito S, Mantel CR, Han MK, Basu S, Fukuda S, Cooper S, Broxmeyer HE (2007) Mad2 is required for optimal hematopoiesis: Mad2 associates with c-Kit in MO7e cells. Blood 109: 1923 – 1930
52. Leung CG, Xu Y, Mulas K, Liu H, Gurbuxani S, Crispino JD (2007) Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 204: 1603 – 1611
53. Gurbuxani S, Xu Y, Reethvansas G, Wickrema A, Crispino JD (2005) Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA 102: 11480 – 11485
54. Goldenson B, Kirsammer G, Stankiewicz MJ, Wen Qj, Crispino JD (2015) Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation. Blood 125: 2141 – 2150
55. Sanjiv K, Hagenkort A, Calderon-Montano JM, Koolmeister T, Reaper PM, Mortusewicz O, Jacques SA, Kuiper RV, Schultz N, Scobie M et al (2016) Cancer-specific synthetic lethality between ATR and CHK1 kinase activities. Cell Rep 17: 3407 – 3416
56. Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D (2017) The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun 8: 1679
57. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847 – 849
58. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM (1999) Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 96: 14943 – 14948
59. Kolke M, Voigt G, Molnar C, Murad F, Bertele D, Krombholz CF, Bohler S, Labi V, Schiller S, Kunze M et al (2017) Transient apoptosis inhibition in donor stem cells improves hematopoietic stem cell transplantation. J Exp Med 214: 2967 – 2983
60. Schuler F, Baumgartner F, Klepsch V, Chamson M, Muller-Holzner E, Watson CJ, Oh S, Hennighausen L, Tymoshuk P, Doppler W et al (2016) The BHS3-only protein BIM contributes to late-stage involution in the mouse mammary gland. Cell Death Differ 23: 41 – 51

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.